GALT
NASDAQ
US
Galectin Therapeutics Inc. - Common Stock
$2.67
▼ $-0.01
(-0.37%)
Vol 243K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$268.2M
ROE
-258.6%
D/E
1108.78
Beta
1.03
52W
$1–$7
Wall Street Consensus
7 analysts · Apr 20262
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
ACHV
Achieve Life Sciences Inc
$264.6M
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
CNTB
Connect Biopharma Holdings Ltd
$157.6M
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
Earnings
Beat rate: 60.0%
Next Report
May 13, 2026
EPS Estimate: $-0.06
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.06 | — | — |
| Dec 2025 | $-0.10 | $-0.08 | +$0.02 |
| Sep 2025 | $-0.11 | $-0.13 | $-0.02 |
| Jun 2025 | $-0.16 | $-0.12 | +$0.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$11.2M | -$12.0M | -$9.6M | -$7.5M | -$8.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -258.6% | -258.6% | -258.6% | -258.6% | -258.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 1108.78 | 1108.78 | 1108.78 | 1108.78 | 1108.78 |
| Current Ratio | 1.43 | 1.43 | 1.43 | 1.43 | 0.09 | 0.09 |
Key Ratios
ROA (TTM)
-268.9%
P/B
46.9
EPS (TTM)
$-0.59
52W High
$7.13
52W Low
$0.76
$0.76
52-Week Range
$7.13
Financial Health
Free Cash Flow
-$3.5M
Net Debt
$110.8M
Cash
$11.5M
Total Debt
$122.3M
As of Sep 30, 2025
How does GALT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GALT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
46.9
▲
1806%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GALT profitability vs Biotechnology peers
ROE
-258.6%
▼
284%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-268.9%
▼
476%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
GALT financial health vs Biotechnology peers
D/E ratio
1108.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
0.1
▼
98%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.0
▲
7%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
GALT fundamentals radar
GALT
Peer median
Industry
GALT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GALT vs peers: key metrics
Latest News
No related news yet